✦ LIBER ✦

Risk-Benefit Ratio of Angiotensin Antagonists versus ACE Inhibitors in End-Stage Renal Disease

✍ Scribed by Dr Domenic A. Sica, Todd W.B. Gehr, Andrea Fernandez

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Angiotensin-converting enzyme inhibitors

✍ Campbell, Heather M.; Khan, Nasreen; Raisch, Dennis W.; Borrego, Matthew E.; Sat 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 504 KB

Distinct time courses of renal protectiv

✍ Matsuda, H; Hayashi, K; Saruta, T 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 115 KB

Angiotensin Converting Enzyme Inhibitors

✍ Inampudi, Chakradhari; Cotarlan, Vladimir 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 401 KB

Maps of end-stage renal disease and amou

✍ Usami, Takeshi; Nakao, Naoyuki; Fukuda, Michio; Takeuchi, Oki; Kamiya, Yoshinobu 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 107 KB

Practical Guidelines for Drug Therapy in

✍ Domenic A. Sica; Todd W. B. Gehr 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 1000 KB

Impact of the Angiotensin II Receptor An

✍ SHIBASAKI, Yasunobu; NISHIUE, Takashi; MASAKI, Hiroya; TAMURA, Koji; MATSUMOTO, 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 344 KB